ASRS top 10: Geographic atrophy burden, Syfovre updates most popular topics
Click Here to Manage Email Alerts
Healio’s recent coverage of the American Society of Retina Specialists annual meeting included a study about the burden of geographic atrophy and updates on Syfovre inflammation reports.
Check out these articles and other popular ASRS items below, and continue to follow Healio for ongoing coverage from the meeting.
Image: Adobe Stock
Burden of geographic atrophy high on patients, caregivers
In the U.S. and Canada, the burden of geographic atrophy on patients and caregivers is “substantial and multifaceted.” Read more.
ASRS ReST Committee sheds light on timeline of Syfovre inflammation reports
The first report of panuveitis with retinal occlusive vasculitis was received by ReST’s reporting system on July 3. ReST contacted Apellis to discuss safety concerns on July 5 and received reports of six additional cases over the next week. Read more.
Cognitive outcomes not significantly different after ROP treatment with bevacizumab, laser
There was no significant difference in cognitive outcomes for patients with retinopathy of prematurity treated with intravitreal bevacizumab compared with those treated with laser photocoagulation. Read more.
Consider possibility of infection, syphilis when managing uveitis
Chronic and recurrent uveitis requires chronic treatment. Read more.
Infliximab may improve visual acuity in PVR associated with RRD
Patients with proliferative vitreoretinopathy experienced improved visual acuity after receiving an intravitreal injection of infliximab after pars plana vitrectomy. Read more.
Apellis: No drug product, manufacturing issues contributed to Syfovre inflammation reports
Apellis Pharmaceuticals reported there is no indication that drug product or manufacturing issues contributed to recent reports of retinal vasculitis linked with Syfovre. Read more.
Etiology of unexplained vision loss after silicone oil removal still unclear
Cases of unexplained vision loss following silicone oil tamponade removal have been reported over the years. Potential causes have been investigated but remain unclear. Read more.
VIDEO: EyePoint presents update on phase 2 trial of EYP-1901 for wet AMD
Nancy Lurker discusses an update on the ongoing phase 2 DAVIO 2 trial, as well as the demographic data in the completed phase 1 DAVIO 1 trial and the DAVIO 2 trial. Watch here.
VIDEO: AI tools useful for monitoring disease activity with pegcetacoplan treatment
Ursula Schmidt-Erfurth, MD, discusses the efficacy of AI algorithms in measuring geographic atrophy lesion growth with pegcetacoplan treatment. Watch here.
VIDEO: Opthea presents update on sozinibercept for wet AMD
Megan Baldwin, PhD, provides an update on OPT-302, now called sozinibercept, for the treatment of neovascular age-related macular degeneration. Watch here.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts